CAR-T Therapy Beyond Cancer: Expanding Horizons in Immune Modulation and Disease Management

Abstract

Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized hematologic oncology, but recent research demonstrates its potential beyond cancer. This comprehensive review explores the scientific rationale, clinical evidence, and translational opportunities for CAR-T therapy in autoimmune and infectious diseases. The article synthesizes the latest guideline-based information, provides mechanism-based insights, and discusses practical implications for healthcare professionals considering CAR-T in nonmalignant indications.

Introduction

CAR-T therapy, initially developed for refractory hematological malignancies, involves genetically engineering T-cells to express synthetic receptors targeting specific antigens. Its success in B-cell malignancies prompted exploration of its utility in other diseases with immune dysregulation or pathogenic cell populations. This review critically examines advances in CAR-T therapy beyond oncology, emphasizing its clinical relevance, underlying mechanisms, and evolving therapeutic landscape for physicians and healthcare professionals.

Epidemiology / Disease Burden

While the global burden of cancer remains substantial, nonmalignant diseases such as autoimmune disorders (e.g., systemic lupus erythematosus, multiple sclerosis) and certain refractory infections (e.g., HIV, chronic hepatitis B) account for significant morbidity and mortality. Autoimmune diseases affect up to 5–8% of the population worldwide, often leading to chronic disability. Conventional immunosuppression can be inadequate or associated with adverse effects, underscoring the need for targeted therapies. The emergence of CAR-T as a precision immunotherapy offers hope for patients with recalcitrant immune-mediated conditions and chronic infections where existing treatments fail.

Pathophysiology

CAR-T therapy leverages the immune system’s cytotoxic potential by redirecting T-cells to specific targets. In cancer, this involves targeting malignant cell antigens (such as CD19 in B-cell malignancies). In autoimmune diseases, autoreactive lymphocytes or pathogenic B-cell subsets drive tissue damage. CAR-T constructs can be engineered to deplete these autoimmune effectors, such as CD19-directed CAR-Ts eliminating pathogenic B-cells in lupus. In infectious diseases, CAR-Ts may target viral reservoirs or infected cells, as seen in experimental HIV CAR-T constructs. The therapeutic rationale is grounded in disrupting disease-driving cellular populations with high specificity, minimizing off-target effects compared to broad immunosuppression.

Risk Factors

Patient selection for CAR-T therapy in non-cancer settings must consider disease activity, prior immunosuppressive exposure, and comorbidities. Risk factors for adverse events include high disease burden, preexisting organ dysfunction (notably cardiac, hepatic, or renal), and prior exposure to cytotoxic agents. In autoimmune diseases, prolonged inflammation can predispose to heightened cytokine release syndrome (CRS) or infectious complications. For infectious diseases, immune restoration or hyperactivation could unmask latent infections or precipitate immune reconstitution syndromes. Careful risk stratification and multidisciplinary assessment are crucial in clinical trials and off-label applications.

Clinical Features

The clinical presentation of patients eligible for CAR-T beyond oncology varies by indication. In autoimmune diseases, refractory multi-organ involvement, persistent serological activity, and failure of standard therapies are typical. For infectious indications, relapsing or persistent viremia despite optimized antiviral therapy suggests eligibility. The expected clinical course post-CAR-T may include rapid depletion of target cell populations, transient cytopenias, and immune reconstitution phenomena. Close monitoring for CRS, neurotoxicity, and infectious complications is essential, as these features overlap with oncologic CAR-T toxicities but may manifest differently due to underlying immune dysregulation.

Diagnosis

Diagnosis of candidate diseases for CAR-T therapy relies on established clinical and laboratory criteria. Autoimmune conditions are defined by serological markers, clinical criteria (e.g., SLEDAI for lupus), and histopathology when available. Infectious disease candidates require virological, immunological, and sometimes molecular diagnostics to identify persistent reservoirs or resistant strains. Baseline immune profiling, organ function assessment, and exclusion of active infections or malignancies are mandatory prior to CAR-T administration. Emerging diagnostics, such as single-cell sequencing, may refine patient stratification and predict response or adverse events.

Treatment & Management

CAR-T therapy for non-cancer indications follows a similar manufacturing process: leukapheresis, T-cell engineering, expansion, and reinfusion. Preconditioning chemotherapy (e.g., fludarabine/cyclophosphamide) is often used to enhance engraftment. For autoimmune diseases, CD19 CAR-T has shown promise in small series, inducing durable remissions in refractory SLE and other disorders. Management involves inpatient monitoring for early detection of CRS or neurotoxicity, immunosuppressive rescue (e.g., tocilizumab, corticosteroids), and supportive care. In infectious disease trials, safety protocols include adjunctive antimicrobials, viral load monitoring, and immune function surveillance. Long-term management addresses potential hypogammaglobulinemia and late immune effects.

Recent Advances / Emerging Therapies

Recent clinical studies have reported encouraging outcomes with CAR-T therapy in nonmalignant diseases. In 2022, landmark reports described complete clinical and serological remission of refractory SLE with CD19-directed CAR-T cells, accompanied by durable B-cell aplasia and normalization of autoantibody levels. Other targets, such as BCMA for plasma cell-driven diseases and CD22 in autoimmune cytopenias, are under active investigation. In infectious diseases, HIV-specific CAR-Ts engineered with dual targeting or antiviral payloads have demonstrated in vitro and early-phase clinical efficacy. Advances in CAR design including logic-gating, transient CAR expression, and allogeneic CAR-Ts may minimize toxicity and improve safety in noncancer populations.

Guideline Recommendations

Formal guidelines for CAR-T therapy in non-cancer indications are still evolving. The American Society for Transplantation and Cellular Therapy (ASTCT) and related bodies recommend CAR-T use in clinical trials or highly selected compassionate cases outside oncology, with robust informed consent and long-term follow-up. Ongoing trials are expected to inform future recommendations regarding patient selection, preconditioning regimens, and post-infusion management. Multidisciplinary collaboration between rheumatology, infectious disease, immunology, and cellular therapy teams is essential for safe and effective clinical implementation.

Conclusion

CAR-T therapy represents a paradigm shift in immune modulation, with growing evidence supporting its application beyond cancer. Early experience in autoimmune and infectious diseases reveals potent efficacy and the potential for durable disease control, although safety and patient selection remain paramount. Continued research, careful clinical monitoring, and guideline development will be key to integrating CAR-T into broader therapeutic armamentaria for nonmalignant diseases. As our understanding of immunopathogenesis deepens and CAR platforms evolve, the transformative impact of CAR-T therapy is poised to extend well beyond oncology, offering new hope for patients with previously untreatable disorders.